0001021771-24-000044.txt : 20240215
0001021771-24-000044.hdr.sgml : 20240215
20240215161135
ACCESSION NUMBER: 0001021771-24-000044
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALSTODT LANCE
CENTRAL INDEX KEY: 0001756228
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37603
FILM NUMBER: 24643921
MAIL ADDRESS:
STREET 1: BIORESTORATIVE THERAPIES, INC.
STREET 2: 40 MARCUS DRIVE, SUITE 1
CITY: MELVILLE
STATE: NY
ZIP: 11747
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioRestorative Therapies, Inc.
CENTRAL INDEX KEY: 0001505497
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 301341024
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 MARCUS DRIVE
CITY: MELVILLE
STATE: NY
ZIP: 11747
BUSINESS PHONE: (631) 760-8100
MAIL ADDRESS:
STREET 1: 40 MARCUS DRIVE
CITY: MELVILLE
STATE: NY
ZIP: 11747
FORMER COMPANY:
FORMER CONFORMED NAME: Stem Cell Assurance, Inc.
DATE OF NAME CHANGE: 20101110
4
1
form4.xml
X0508
4
2024-02-13
0001505497
BioRestorative Therapies, Inc.
BRTX
0001756228
ALSTODT LANCE
BIORESTORATIVE THERAPIES, INC.
40 MARCUS DRIVE, SUITE 1
MELVILLE
NY
11747
true
true
true
President, CEO, COB
false
Common Stock
189505
D
Stock Option
5.08
2031-03-18
Common Stock
293479
293479
D
Stock Option
5.08
2031-11-04
Common Stock
42059
42059
D
Stock Option
2.91
2033-02-17
Common Stock
106762
106762
D
Stock Option
1.45
2024-02-13
4
A
0
438596
0
A
2034-02-13
Common Stock
438596
438596
D
Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024.
The option is currently exercisable.
The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
The option vests and becomes exercisable to the extent of 219,298 shares on February 13, 2024 and 219,298 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
/s/ Lance Alstodt
2024-02-13